Connect Biopharma Q3 net loss narrows 6% to $16.2 million
CNTB•Connect Biopharma’s third-quarter 2026 net loss narrowed 6% year over year to $16.2 million. Revenue was $700,000, research and development expenses rose 15% to $12.8 million, and cash and short-term investments totaled $19.5 million at September 30.
1. Quarterly results
Connect Biopharma’s third-quarter 2026 net loss narrowed 6% year over year to $16.2 million. License and collaboration revenues rose to $700,000, primarily from cost reimbursements for development activities. Research and development expense increased 15% to $12.8 million due to higher rademikibart-related development costs.
2. Cash and FDA discussions
Cash, cash equivalents and short-term investments totaled $19.5 million at September 30, 2026. The company plans discussions with the FDA on potential Phase 3 rademikibart programs in December 2026 for asthma and in the first quarter of 2027 for COPD.




